SCHEMBL17700014

SCHEMBL17700014

Cc1c(C)n(C(=O)O)c2ccc(F)c(Br)c12

nearest known ligand 0.34

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
DAO P14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17700032 0.81 MEN1 (0.32)
SCHEMBL28246281 0.70 ALDH1A1 (0.35) AKR1B1DAO
SCHEMBL1757919 0.69 AKR1C3 (0.44) AKR1B1PTGDR2
SCHEMBL16741834 0.68 BAZ2B (0.41)
SCHEMBL30993669 0.64 EPRS1 (0.41)
SCHEMBL4495727 0.64 EPRS1 (0.41)
SCHEMBL1075595 0.64 POLB (0.48)
SCHEMBL31668450 0.62 ALDH1A1 (0.54)
SCHEMBL27504693 0.62 ALDH1A1 (0.54)
SCHEMBL16741688 0.62 GAA (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2023-06-22 US disclosed
US-11623921-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2023-04-11 US disclosed
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2021-04-15 US disclosed
US-20200165222-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2020-05-28 US disclosed
EP-3461821-B1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-05-13 EP disclosed
EP-3209656-B1 INDOLE CARBOXAMIDES COMPOUNDS USEFUL AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-04-01 EP disclosed
US-10604504-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-31 US disclosed
US-20190248760-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2019-08-15 US disclosed
US-10329274-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2019-06-25 US disclosed
US-20190119245-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2019-04-25 US disclosed
EP-3461821-A1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2019-04-03 EP disclosed
US-9920031-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-20 US disclosed
US-9802915-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-31 US disclosed
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US disclosed
EP-3209656-A1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 EP disclosed
US-9688629-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2017-06-27 US disclosed
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-03-09 US disclosed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248760-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20230192645-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-10329274-B2 Indole carboxamide compounds BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20170066740-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-11623921-B2 Indole carboxamide compounds BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20190119245-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20210107891-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-20200165222-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885
US-10604504-B2 Indole carboxamide compounds BTK, JAK2, BRD4 AKR1B1 2601/4885PTGDR2 1941/4885DAO 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.